In value terms, orphan designated drugs-related deal activity increased by 14% in Q1 2024 compared with the previous quarter’s total of $440.1m and rose by 236% as compared to Q1 2023. Related deal volume decreased by 50% in Q1 2024 versus the previous quarter and was 40% lower than in Q1 2023.

The top-ranked legal advisors supporting these private equity deals in Q1 2024 were Cooley; Kirkland & Ellis; Latham & Watkins with 1, 1, 1 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.